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Abstract
A complementary DNA for the angiotensin II (AngII) type 1 (AT1) receptor from Mustela putorius furo (ferret) was
isolated from a ferret atria cDNA library. The cDNA encodes a protein (fAT1) of 359 amino acids having high homologies
(93^99%) to other mammalian AT1 receptor counterparts. When fAT1 was expressed in COS-7 cells and photoaffinity
labeled with the photoactive analogue 125I-[Sar1, Bpa8]AngII, a protein of 100 kDa was detected by autoradiography. The
formation of this complex was specific since it was abolished in the presence of the AT1 non-peptidic antagonist L-158,809.
Functional analysis indicated that the fAT1 receptor efficiently coupled to phospholipase C as demonstrated by an increase in
inositol phosphate production following stimulation with AngII. Binding studies revealed that the fAT1 receptor had a high
affinity for the peptide antagonist [Sar1, Ile8]AngII (Kd of 5.8 þ 1.4 nM) but a low affinity for the AT1 selective non-peptidic
antagonist DuP 753 (Kd of 91 þ 15.6 nM). Interestingly, when we substituted Thr163 with an Ala residue, which occupies this
position in many mammalian AT1 receptors, we restored the high affinity of this receptor for Dup 753 (11.7 þ 5.13 nM).
These results suggest that position 163 of the AT1 receptor does not contribute to the overall binding of peptidic ligands but
that certain non-peptidic antagonists such as Dup 753 are clearly dependent on this position for efficient binding. ß 2000
Elsevier Science B.V. All rights reserved.
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1. Introduction
The octapeptide angiotensin II (AngII) is the prin-
cipal agent of the renin^angiotensin system, with ef-
fects that include vasoconstriction, release of aldoste-
rone and vasopressin, cardiac stimulation and renal
reabsorption of sodium as well as cellular prolifera-
tion [1,2]. AngII is implicated in pathologies such as
hypertension, atherosclerosis, renal insu⁄ciency,
heart failure and cardiac hypertrophy [3] but also
participates in restenosis following percutaneous
transluminal coronary angioplasty [4]. The develop-
ment of selective non-peptide analogues of AngII has
enabled investigators to distinguish two pharmaco-
logically distinct subtypes of AngII receptors termed
AT1 and AT2 which show selectivity for the non-
peptide antagonist DuP 753 (Losartan) and
PD123319, respectively [5^7]. The AT1 receptor is a
member of the large family of G-protein coupled
receptors (GPCRs) and mediates the major physio-
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logical actions of AngII. Complementary DNA
structures of both AT1 and AT2 receptors have
been determined in mammalian, avian and amphib-
ian species. The ¢rst AT1 receptor to be cloned is the
rat AT1A receptor followed by cow, human, mouse,
rabbit, pig, dog (see [8] for review) and more recently
gerbil [9]. In addition, cDNA sequences for turkey,
chicken and xenopus AT1 receptors have been re-
ported.
It had been demonstrated that AngII could di-
rectly or indirectly mediate neointimal proliferation
of smooth muscle following arterial injury [3,10]. To
evaluate whether the ferret could provide a novel and
suitable non-rodent model to be used in characteriz-
ing the role of AngII in post-angioplastic restenosis,
our group has recently been using this species. Other
groups have shown how this particular animal could
be advantageous for studying the pharmacology of
receptor antagonists within the cardiovascular system
[11,12]. Experiments assessing the e⁄cacy of non-
peptide AT1 receptor antagonists in preventing reste-
nosis revealed an ine⁄ciency of Losartan in the ferret
model compared to the rat (unpublished results). To
further investigate this observation, we set out to
clone the cDNA encoding the AT1 receptor of the
ferret and determine its functional properties by ex-
pressing the receptor protein in COS-7 cells.
2. Materials and methods
2.1. Cloning of fAT1
An oligo-dT primed ferret atria cDNA library con-
structed in Vgt10 was obtained from Merck Research
Laboratories (West Point, PA, USA). Reverse tran-
scription-polymerase chain reaction (RT-PCR) was
used to amplify a gene fragment from 1 Wg of ferret
kidney total RNA using oligonucleotide probes
based on the rat AT1A cDNA [13]. This fragment,
comprised of 433 nucleotides, was ampli¢ed with an
oligonucleotide, 5’-GAGATTGGTATAGAAATG-
GCTG-3’, corresponding to nucleotides 3123 to
3102 and a second oligonucleotide, 5’-CGATCTTA-
CATAGGTGATTGC-3’, spanning nucleotides 290
to 310 of the rat sequence. Following reverse-tran-
scription, ampli¢cation was achieved using the fol-
lowing reaction conditions: 35 cycles at 94‡C for
60 s, 50‡C for 60 s and 72‡C for 180 s with an ex-
tension period of 10 min at the end of the cycles
using a Perkin-Elmer 480 PCR apparatus. The RT-
PCR product was separated on a gel and the 433 bp
band excised and quantitated prior to being labeled
with 32P. Approximately 106 plaques from a ferret
atria cDNA library constructed in Vgt10 were
screened with this probe. Three successive rounds
of library screening were performed according to
standard protocols [14] which resulted in two
strongly positive clones. These cDNA inserts were
excised with EcoRI and subcloned into the expres-
sion plasmid pcDNA3 (Invitrogen, USA) and nucle-
otide sequence analysis was performed.
2.2. Site-directed mutagenesis and expression of fAT1
To construct the mutant receptor which contains
the T163A substitution, the cDNA insert encoding
the wild-type fAT1 receptor was excised with Hin-
dIII/XbaI from pcDNA3 and subcloned in
M13mp19 RF. A mutagenic oligonucleotide T163A
(5’-GGTGGATTATAGCTGGCAAACTGGC-3’)
and the Sculptor mutagenesis kit (Amersham) were
used to perform site-directed mutagenesis. The mu-
tated insert was ¢nally subcloned HindIII/XbaI into
pcDNA3 (Invitrogen) and sequenced prior to trans-
fection.
For expression of ferret AT1 receptor, COS-7 cells
were grown in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) containing 2 mM L-glutamine, 100 IU/ml
penicillin, 100 mg/ml streptomycin and 10% (v/v) fe-
tal bovine serum. Cells were seeded into 75 cm2 cul-
ture dishes, washed once with serum-free DMEM
and transfected with 4 Wg of pcDNA3 vector con-
taining ferret AT1 receptor and 25 Wl of lipofectam-
ine (Gibco BRL) in 8 ml of serum-free DMEM. The
cells were incubated for 5 h at 37‡C and the media
was replaced with complete DMEM medium con-
taining 100 IU/ml penicillin and 100 mg/ml strepto-
mycin. Transfected cells were grown for 48 h before
binding assays, phospholipase C assays or photoaf-
¢nity labeling.
2.3. Binding experiments
COS-7 cells were grown for 48 h posttransfection
in 100 mm dishes, washed once with phosphate bu¡-
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ered saline and subjected to one freeze^thaw cycle.
COS-7 cells membranes (V40 Wg) were incubated in
a medium containing 25 mM Tris^HCl (pH 7.4), 100
mM NaCl, 5 mM MgCl2, 0.1% bovine serum albu-
min (BSA) and 0.01% bacitracin in the presence of
125I-[Sar1, Ile8]AngII and selected concentrations of
[Sar1, Ile8]AngII or AngII analogues in a ¢nal incu-
bation volume of 500 Wl. Incubations were performed
at room temperature for 90 min. Non-speci¢c bind-
ing was determined in the presence of 1 WM AngII.
Bound radioactivity was separated from free ligand
by ¢ltration through A/E glass ¢ber ¢lters presoaked
for at least 2 h in the binding bu¡er. The receptor-
bound radioactivity was analyzed by gamma count-
ing.
2.4. Phospholipase C assays
To determine the functionality of fAT1, COS-7
cells, subcultured in six well plates, were labeled
with 15 WCi/ml myo-[3H]inositol for 18 h after trans-
fection. Cells were subsequently incubated with in-
creasing concentrations of AngII at 37‡C for 20
min in the presence of 10 mM LiCl and inositol
phosphate levels were measured as described previ-
ously [15].
2.5. Photoa⁄nity labeling
For photoa⁄nity labeling, membranes from COS-
7 cells transfected with fAT1 were incubated in 1 ml
of binding bu¡er containing 25 mM Tris^HCl, pH
7.4, 100 mM NaCl, 5 mM MgCl2, 0.1% BSA and
125I-[Sar1, Bpa8]AngII (5 nM) in the absence or pres-
ence of AngII (1 WM), L-158,809 (1 WM) or
PD123319 (1 WM) as previously reported [15]. After
60 min at room temperature, cells were brie£y
washed with 1 ml of ice-cold binding bu¡er (without
BSA) and irradiated for 60 min at 0‡C under ¢ltered
UV light (365 nm) (mercury vapor lamp serial num-
ber 5873 from Westinghouse and Raymaster black
light ¢lters number 5873 from Gates and Co., Long
Island, NY, USA). Cells were then gently scraped
with a rubber policeman and centrifuged (3000
rpm) for 10 min at 4‡C. The pellet was solubilized
in m-RIPA bu¡er (50 mM Tris^HCl, pH 7.4, 150
mM NaCl, 1% NP-40, 0.1% deoxycholate). After
centrifugation (13 000 rpm for 10 min at 4‡C), the
supernatants containing the labeled proteins were an-
alyzed by 7.5% sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE), followed
by autoradiography on X-ray ¢lms (Kodak Biomax
MS).
3. Results
3.1. Cloning of the fAT1 receptor
Using a combination of RT-PCR and phage li-
brary screening of a ferret (Mustela putorius furo)
atria cDNA library we obtained two clones contain-
ing inserts of 3.2 kb. These two clones were se-
quenced and revealed to contain an 1080 bp open
reading frame (Fig. 1) encoding a polypeptide of
359 residues with marked homology to other cloned
AT1 receptors (Fig. 2). Interspecies comparison indi-
cates that this clone has its highest sequence identity
(99%) with the AT1 receptor of Canis familiaris at
the amino acid level. The fAT1 receptor was also
highly homologous with other mammalian AT1 re-
ceptors: Sus scrofa (96%), Homo sapiens AT1a (95%),
Bos taurus (94%), Oryctolagus cuniculus (94%), H.
sapiens AT1b (93%), Mus musculus AT1a (93%), Rat-
tus norvegicus AT1a (93%), R. norvegicus AT1b (92%),
Meriones unguiculatus (91%), M. musculus AT1b
(91%). These similarities then dropped when com-
pared with sequences for avian species like Meleagris
gallopavo (75%), Gallus gallus (75%) or amphibian
Xenopus laevis (63%). The fAT1 receptor has low
homologies to AT2 receptors.
The protein sequence deduced from the nucleotide
sequence possesses many of the characteristic fea-
tures found in most GPCRs: [1] the existence of
seven hydrophobic regions that are likely to repre-
sent the membrane spanning domains found among
the G-protein-linked receptor superfamily; [2] the
protein contains three potential N-glycosylation
sites: Asn4 present in the amino terminal region
and two others, Asn176 and Asn188, present in
the second extracellular loop; [3] four cysteine resi-
dues (Cys18, 101, 180 and 274) that are thought to
cross-link extracellular loops by disul¢de bonding;
[4] several serine and threonine residues, putative
substrates for phosphorylation by protein kinase C
or GPCR kinase, are present in the third intracellular
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loop and the carboxyl-terminal tail of the receptor
(Fig. 2).
3.2. Expression and functionality of the fAT1 receptor
Con¢rmation that this clone is an angiotensin re-
ceptor and characterization of its pharmacological
and biochemical properties required its expression
in a eukaryotic system. The 3.2 kb cDNA insert
was digested with AseI and HindIII restriction en-
zymes and a fragment of 1261 bp containing the
coding region was subcloned in pcDNA3. As a ¢rst
step in determining whether the cDNA encoded an
AT1 receptor, COS-7 cells transfected with plasmid
encoding fAT1 were photolabeled with 125I-[Sar1,
Bpa8]AngII and proteins were subjected to SDS^
Fig. 1. Nucleotide and deduced amino acid sequences of the ferret AT1 receptor. Bases are numbered 5’ to 3’. The seven putative
transmembrane domains are underlined.
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PAGE. The autoradiogram showed that the 125I-
[Sar1, Bpa8]AngII/fAT1 complex migrates as a broad
band of 100 kDa apparent molecular mass (Fig. 3,
lane 1) consistent with results previously reported on
the human AT1 [15]. The labeling was speci¢c since it
was abolished in the presence of AngII or L-158,809
(lanes 2 and 3) whereas incubation with the AT2
selective ligand PD123319 had no e¡ect (lane 4).
The functional properties of the fAT1 receptor
were evaluated by assessing the AngII-induced inosi-
tol phosphate accumulation within transiently trans-
fected COS-7 cells. Fig. 4 shows that activation of
phospholipase C within fAT1-transfected COS-7 cells
reached a plateau at 1038 M AngII. Control cells
transfected with the plasmid pcDNA3 alone had
basal IP2+IP3 levels of approximately 2000^2500
Fig. 2. Comparison of the deduced amino acid sequence of ferret AT1 receptor to those of other mammalian AT1 receptors. Identical
amino acids are represented by (-). Potential N-linked glycosylation sites are represented by (*), potential protein kinase C phosphory-
lation sites in the ferret receptor by (b) and cysteine residues responsible of disul¢de bonding by (S). The single letter amino acid
code is used throughout.
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cpm, which were not enhanced after treatment with
AngII (100 nM) (data not shown). The maximum
response corresponding to 100 nM AngII was
13 615 þ 698 cpm and the basal response was
1751 þ 103 cpm. The half-maximal response (EC50)
of the fAT1 receptor is 0.73 þ 0.59 nM. These results
suggest that the fAT1 cDNA encodes a functional
receptor coupled to a heterotrimeric protein belong-
ing to the Gq family of G-proteins which activates
the phospholipase C signaling pathway.
3.3. Binding properties of fAT1 and T163AfAT1
receptors
Saturation binding experiments performed on
fAT1 transfected COS-7 cells demonstrated that
the expressed receptor bound 125I-labeled [Sar1,
Fig. 5. Binding of ligands to fAT1. (a) Saturation binding iso-
therm of 125I-[Sar1, Ile8]AngII to COS-7 cells transfected with
the fAT1 cDNA. Membranes (V40 Wg of protein) were incu-
bated at room temperature for 90 min in binding bu¡er with
increasing concentrations of 125I-[Sar1, Ile8]-AngII. Non-speci¢c
binding was determined in the presence of 1 WM [Sar1, Ile8]-
AngII. Inset: Scatchard plot of the same binding data. Each
point represents the mean þ S.D. of triplicate determinations.
Similar data were obtained in ¢ve separate experiments. (b)
Concentration-dependent inhibition of 125I-[Sar1, Ile8]-AngII
binding to fAT1 COS-7 membranes with unlabeled ligands.
Membranes (V40 Wg of protein) were incubated for 90 min at
room temperature with 125I-[Sar1, Ile8]AngII and increasing
concentrations of [Sar1, Ile8]-AngII (R) L-158,809 (E), AngII
(8), Losartan (F), PD123319 (7), bradykinin (b), vasopressin
(O). Each curve represents the mean of at least three independ-
ent experiments with each point performed in triplicate. The
variation between triplicates was less than 10%.
Fig. 4. Ins (1,4,5)P3 production in transfected COS-7 cells. At
24 h after the initial transfection, cells expressing fAT1 were
prelabeled for 18 h with myo-[3H]inositol. IP2 and IP3 were
measured after cells were stimulated with increasing concentra-
tions of AngII. Data are expressed as mean þ S.D. of triplicate
values and are representative of three independent experiments.
Fig. 3. Photoa⁄nity labeling of fAT1 receptor expressed in
COS-7 cells. Transfected cells were incubated with 125I-[Bpa8]-
AngII (6 nM) in the absence (lane 1) or presence of AngII (1
WM) (lane 2), L-158,809 (1 WM) (lane 3) and PD123319 (1 WM)
(lane 4) and were subjected to UV irradiation. Irradiated mate-
rial was resolved by 7.5% SDS^PAGE followed by autoradiog-
raphy. Protein standards of the indicated molecular masses
(kDa) were run in parallel. These results are representative of
three separate experiments.
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Ile8]AngII in a concentration-dependent and satur-
able manner (Fig. 5a). Scatchard analysis of the
data revealed a single binding site with an estimated
Kd of 0.79 þ 0.36 nM and an average binding ca-
pacity (Bmax) of approximately 0.39 þ 0.15 pmol/mg
of protein (Fig. 5a, inset). This binding is inhibited
by a variety of angiotensin agonists and antagonists
with pharmacological pro¢les represented in Fig. 5b.
AngII and [Sar1, Ile8]AngII interacted with the re-
ceptor with Kds of 5.8 þ 1.4 and 1.1 þ 0.7 nM, respec-
tively. Likewise, the non-peptide AT1 receptor-selec-
tive antagonists Losartan and L-158,809 also
inhibited binding, exhibiting Kd values of 91 þ 15.6
and 1.7 þ 1.2 nM, respectively.
Using dose^displacement experiments, we then
compared the wild-type fAT1 receptor or the
T163AfAT1 receptor with regards to their a⁄nity
for Losartan. Interestingly, we found that substitu-
tion of threonine 163 for alanine drastically im-
proved the receptor’s a⁄nity for Losartan with a
Kd value of 11.7 þ 5.13 nM (Fig. 6). The AT2 speci¢c
non-peptide antagonist, PD123319 and the unrelated
peptides bradykinin and vasopressin at a concentra-
tion of 1036 M had no e¡ect on binding on either the
wild-type or mutant receptors.
4. Discussion
In this study, we have cloned, expressed and char-
acterized the ferret AT1 receptor. It di¡ers from the
canine AT1 receptor [16] by three amino acid substi-
tutions: Leu 128, Arg 137 and Leu 138. When ex-
pressed in COS-7 cells, the fAT1 receptor exhibits
very similar pharmacology to the canine, bovine
[17] and porcine AT1 receptor [18] in terms of its
high a⁄nity for AngII, its insensitivity to
PD123319 and its reduced a⁄nity for Losartan.
The calculated Kd for Losartan on the ferret receptor
is 91 nM, similar to 92 nM reported for the canine
AT1 receptor [16]. When we compare, at the amino
acid level, the Losartan-insensitive species (ferret, ca-
nine, bovine and porcine), the only shared feature
within an accessible binding site was a threonine at
position 163 found in the fourth transmembrane do-
main which is replaced by an alanine in Losartan-
sensitive species. It had been suggested that this res-
idue could be partly responsible for the decreased
a⁄nity to Losartan [16]. The results obtained herein
with T163AfAT1 con¢rmed that this residue is crit-
ical in promoting a high a⁄nity binding of Losartan
with AT1-like receptors. However, with the recent
cloning of another Losartan-insensitive AT1-like re-
ceptor from gerbil that contains the conserved ala-
nine residue [9], it is clear that there are probably
other determinants that a¡ect the overall conforma-
tion of the binding pocket, making it more or less
available to this non-peptidic antagonist. Site-di-
rected mutagenesis on the AT1 receptor based on
pharmacological di¡erences found between species
had previously shown that speci¢c residues of the
AT1 receptor were critical for losartan binding. For
instance, an amphibian AT1 receptor unresponsive to
Losartan binding acquired a⁄nity for this ligand
upon proper residue replacement based on the di¡er-
ences with mammalian sequences [19] namely the
AT1b receptor from rat. It was previously shown
that a rat V108I AT1b mutant exhibited a 40-fold
reduction in losartan a⁄nity while a⁄nities toward
peptides remained essentially unchanged [20] high-
lighting the importance of this position in recogni-
tion of Losartan. Further studies using various Los-
artan analogs demonstrated how Val108 found in
transmembrane domain 3, is a structural determinant
involved in non-peptide ligand recognition [21].
Proximal amino acids were later shown to be critical
either for the peptide agonist or for Losartan bind-
ing. For example, a mutation of Ser105 into alanine
led to the abolished binding of peptide agonist with
little e¡ect on non-peptide ligands [22]. However,
Fig. 6. Concentration-dependent inhibition of 125I-[Sar1, Ile8]-
AngII binding to fAT1 (E) orT163AfAT1 (F) expressed in
COS-7 membranes with unlabeled Losartan. Conditions similar
to the ones described in Fig. 5 were used.
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replacement of Asn111 resulted in marked losses of
a⁄nity for Losartan [23]. Subsequent to mutations
made to Asn295 in transmembrane domain 7 where-
by similar changes in pharmacological pro¢le were
observed, it was concluded that this substitution
caused a loss of interaction between Asn111 and
Asn295. The participation of Asn294 and Asn295
in ligand binding was also addressed by Hunyady
et al. [24], who demonstrated that an N294A mutant
had diminished receptor binding a⁄nities for AngII,
two non-peptide agonists and Losartan but that its
a⁄nity for [Sar1, Ile8]AngII was una¡ected. In con-
trast, the N295 mutant decreased receptor-binding
a⁄nities for all AngII ligands. Finally, experiments
designed to identify residues of the AT1 receptor
participating in interactions with various pharmaco-
phores (tetrazole, carboxyl) of non-peptide antago-
nists such as Losartan revealed that replacement of
speci¢c basic residues did not alter a⁄nities for these
ligands [25]. However, some of the studied mutants
such as K199Q had reduced a⁄nities only to car-
boxylated ligands including [Sar1, Ile8]AngII.
Coupled with the results presented herein on the
role of residue 163 for e⁄cient Losartan binding,
we suggest that multiple residues found within trans-
membrane domains 3, 4 and 7 participate directly or
indirectly to promote non-peptidic ligand binding.
Moreover, the molecular determinants that are re-
sponsible for forming the binding pocket and which
dictate local structure for proper interactions with
ligands, are probably not totally overlapping. This
same argument would hold true for either agonist
or antagonist ligands.
Development of the non-peptide AngII receptor
antagonists has resulted in a rapid expansion of
our understanding of the role of AngII in physiol-
ogy. These non-peptide antagonists have great poten-
tial value as therapeutic agents in the treatment of
hypertension and cardiac failure. The original clon-
ing of the rat and the bovine AT1 receptors has fur-
nished the opportunity to understand the molecular
nature of the interaction between the AT1-selective
non-peptide antagonists and their target receptors.
This might in turn ultimately lead to the develop-
ment of new antagonists. Clues as to the basis of
this interaction could come from mutagenesis studies
of the receptor or from functional studies of these
antagonist^receptor interactions in other species, es-
sentially exploiting ‘naturally occurring mutagenesis’
experiments.
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